Description du projet
Faire progresser la fabrication de produits biopharmaceutiques
Les médicaments biologiques sont des composés modificateurs de la maladie tels que les cytokines ou les anticorps qui sont produits par des cellules in vitro. Ils sont utilisés pour traiter diverses maladies, notamment les maladies inflammatoires et le cancer. Cependant, la variabilité inhérente des cellules utilisées dans le processus de fabrication pose un défi technique. L’objectif du projet STACCATO, financé par l’UE, est d’améliorer les systèmes de production de cellules existants afin de produire des médicaments biologiques uniformes et sûrs. Le projet consiste à former de jeunes chercheurs aux méthodes expérimentales et informatiques d’analyse de la variabilité et des performances cellulaires pour améliorer la production de médicaments biologiques.
Objectif
Our ability to utilise biological systems to produce medicines has improved the quality of life for millions of EU citizens. In recent years a new wave of exciting biopharmaceuticals have been discovered with the potential to advance current treatments for a variety of disorders. These new medicines, however, are becoming increasingly complex and difficult to manufacture. Overcoming the inherent heterogeneity of cells grown in vitro to produce effective, uniform and safe biopharmaceuticals is one of the most significant challenges faced by industry today.
The STACCATO European Industrial Doctorate has been specifically designed to strengthen Europe’s innovation capacity and leadership in the BioPharma sector. The consortium will provide exceptional intersectoral training to 11 ESRs through pioneering research focused on harnessing recent advances in single cell analysis to generate and apply a new suite of tools for cell culture process development. ESRs will participate in a specialised training programme to build their proficiency in essential research and industry disciplines. Additional training in professional skills and entrepreneurship will enable ESRs to become future leaders in biopharmaceutical manufacturing science.
STACCATO is composed of an industry leader in instrumentation for cellular analysis, 3 innovative biotechnology SMEs, a leading academic institution and a research conducting biological medicines regulatory agency. The STACCATO EID will immerse all ESRs in highly dynamic industrial environments while receiving supervision from leading academics. A feature of STACCATO is collaboration amongst experts in the production of different biopharmaceuticals such as therapeutic proteins and CAR T cell therapy. All ESRs will receive unparalleled exposure to pan-biopharmaceutical manufacturing challenges to foster collaboration, catalyse synergies across the network and ultimately create a truly unique training experience.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
4 Blackrock Dublin
Irlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.